| Jamaluddin Moloo, MD | |
|
12605 E 16th Ave, Aurora, CO 80045 | |
| (720) 848-0000 | |
| Not Available |
| Full Name | Jamaluddin Moloo |
|---|---|
| Gender | Male |
| Speciality | Interventional Cardiology |
| Experience | 33 Years |
| Location | 12605 E 16th Ave, Aurora, Colorado |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235101197 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Colorado Hospital Authority | Aurora, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Uchealth Imaging Services Llc | 5799021291 | 141 |
| University Physicians Incorporated | 3476465667 | 2657 |
News Archive
New research may allow new, more effective and safer pain medications to reach patients who suffer from chronic pain sooner. According to a recent study published in Anesthesiology, the official medical journal of the American Society of Anesthesiologists, using functional magnetic resonance imaging (FMRI), to measure the brain's neural response to pain, may be a viable tool for evaluating the effectiveness of new pain medications during the early stages of human drug development - providing the needed objective evidence to prevent the premature discarding of potentially beneficial therapies.
Manhattan Scientifics announced today that it has entered into a non-binding letter of intent (LOI) with Edward R. Flynn, Ph.D. and his company, Senior Scientific, LLC, to acquire all the manufacturing and marketing rights, together with all commercial rights associated with Dr. Flynn's patents and IP in the emerging field of nanomedicine.
Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces clinical results from ENCORE 401, a double-blind, placebo-controlled phase 2 trial, in patients with advanced non-small cell lung cancer (NSCLC). The results show that there was a survival advantage in the subset of patients with elevated E-cadherin (a molecular marker of epithelial tumors) receiving entinostat in combination with erlotinib (Tarceva®).
Danielle Jones sits at her dining room table, studying the recipe for Nerd Lyfe (v2) vape juice. The supplies she's ordered online are arrayed before her: a plastic jug of unflavored liquid nicotine, a baking scale and bottles of artificial flavors that, combined, promise to re-create the fruity taste of Nerds Rope candy in vapor form.
Bruker Corporation today announced that it has been granted U.S. FDA clearance under Section 510(k) to market its MALDI Biotyper CA System in the United States for the identification of Gram negative bacterial colonies cultured from human specimens.
› Verified 4 days ago
| Entity Name | University Physicians Incorporated |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962461889 PECOS PAC ID: 3476465667 Enrollment ID: O20031105000375 |
News Archive
New research may allow new, more effective and safer pain medications to reach patients who suffer from chronic pain sooner. According to a recent study published in Anesthesiology, the official medical journal of the American Society of Anesthesiologists, using functional magnetic resonance imaging (FMRI), to measure the brain's neural response to pain, may be a viable tool for evaluating the effectiveness of new pain medications during the early stages of human drug development - providing the needed objective evidence to prevent the premature discarding of potentially beneficial therapies.
Manhattan Scientifics announced today that it has entered into a non-binding letter of intent (LOI) with Edward R. Flynn, Ph.D. and his company, Senior Scientific, LLC, to acquire all the manufacturing and marketing rights, together with all commercial rights associated with Dr. Flynn's patents and IP in the emerging field of nanomedicine.
Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces clinical results from ENCORE 401, a double-blind, placebo-controlled phase 2 trial, in patients with advanced non-small cell lung cancer (NSCLC). The results show that there was a survival advantage in the subset of patients with elevated E-cadherin (a molecular marker of epithelial tumors) receiving entinostat in combination with erlotinib (Tarceva®).
Danielle Jones sits at her dining room table, studying the recipe for Nerd Lyfe (v2) vape juice. The supplies she's ordered online are arrayed before her: a plastic jug of unflavored liquid nicotine, a baking scale and bottles of artificial flavors that, combined, promise to re-create the fruity taste of Nerds Rope candy in vapor form.
Bruker Corporation today announced that it has been granted U.S. FDA clearance under Section 510(k) to market its MALDI Biotyper CA System in the United States for the identification of Gram negative bacterial colonies cultured from human specimens.
› Verified 4 days ago
| Entity Name | Uchealth Imaging Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396210902 PECOS PAC ID: 5799021291 Enrollment ID: O20190103002022 |
News Archive
New research may allow new, more effective and safer pain medications to reach patients who suffer from chronic pain sooner. According to a recent study published in Anesthesiology, the official medical journal of the American Society of Anesthesiologists, using functional magnetic resonance imaging (FMRI), to measure the brain's neural response to pain, may be a viable tool for evaluating the effectiveness of new pain medications during the early stages of human drug development - providing the needed objective evidence to prevent the premature discarding of potentially beneficial therapies.
Manhattan Scientifics announced today that it has entered into a non-binding letter of intent (LOI) with Edward R. Flynn, Ph.D. and his company, Senior Scientific, LLC, to acquire all the manufacturing and marketing rights, together with all commercial rights associated with Dr. Flynn's patents and IP in the emerging field of nanomedicine.
Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces clinical results from ENCORE 401, a double-blind, placebo-controlled phase 2 trial, in patients with advanced non-small cell lung cancer (NSCLC). The results show that there was a survival advantage in the subset of patients with elevated E-cadherin (a molecular marker of epithelial tumors) receiving entinostat in combination with erlotinib (Tarceva®).
Danielle Jones sits at her dining room table, studying the recipe for Nerd Lyfe (v2) vape juice. The supplies she's ordered online are arrayed before her: a plastic jug of unflavored liquid nicotine, a baking scale and bottles of artificial flavors that, combined, promise to re-create the fruity taste of Nerds Rope candy in vapor form.
Bruker Corporation today announced that it has been granted U.S. FDA clearance under Section 510(k) to market its MALDI Biotyper CA System in the United States for the identification of Gram negative bacterial colonies cultured from human specimens.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jamaluddin Moloo, MD Po Box 110429, Aurora, CO 80042-0429 Ph: (303) 493-7000 | Jamaluddin Moloo, MD 12605 E 16th Ave, Aurora, CO 80045 Ph: (720) 848-0000 |
News Archive
New research may allow new, more effective and safer pain medications to reach patients who suffer from chronic pain sooner. According to a recent study published in Anesthesiology, the official medical journal of the American Society of Anesthesiologists, using functional magnetic resonance imaging (FMRI), to measure the brain's neural response to pain, may be a viable tool for evaluating the effectiveness of new pain medications during the early stages of human drug development - providing the needed objective evidence to prevent the premature discarding of potentially beneficial therapies.
Manhattan Scientifics announced today that it has entered into a non-binding letter of intent (LOI) with Edward R. Flynn, Ph.D. and his company, Senior Scientific, LLC, to acquire all the manufacturing and marketing rights, together with all commercial rights associated with Dr. Flynn's patents and IP in the emerging field of nanomedicine.
Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces clinical results from ENCORE 401, a double-blind, placebo-controlled phase 2 trial, in patients with advanced non-small cell lung cancer (NSCLC). The results show that there was a survival advantage in the subset of patients with elevated E-cadherin (a molecular marker of epithelial tumors) receiving entinostat in combination with erlotinib (Tarceva®).
Danielle Jones sits at her dining room table, studying the recipe for Nerd Lyfe (v2) vape juice. The supplies she's ordered online are arrayed before her: a plastic jug of unflavored liquid nicotine, a baking scale and bottles of artificial flavors that, combined, promise to re-create the fruity taste of Nerds Rope candy in vapor form.
Bruker Corporation today announced that it has been granted U.S. FDA clearance under Section 510(k) to market its MALDI Biotyper CA System in the United States for the identification of Gram negative bacterial colonies cultured from human specimens.
› Verified 4 days ago
Samiran Bhattacharya, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 1635 Aurora Ct, Aurora, CO 80045 Phone: 720-848-0000 | |
Payal Rohit Patel, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 303-724-6024 | |
Jonathan A Gutman, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 | |
Jeffrey Glasheen, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 | |
Micol Rothman, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 | |
Larry Allen, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 | |
Virginia Borges, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 |